N

Neurocrine Biosciences

Develops and markets neurology-focused therapies

Executive Director - QA Compliance

Full-TimeUpdated on 10/23/2026
$227k - $398k/yr+ 35% target annual bonus + Equity-based long-term incentive program
Expert
Bachelor's, Master's, PhD
San Diego, CA, USA
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in a scientific, engineering, quality, or related applicable field and 16 or more years of applicable experience, or a master's degree in an applicable field and 14 or more years of applicable experience, or a PhD or other advanced degree and 12 or more years of applicable experience.
  • Extensive progressive experience in pharmaceutical or biotechnology Quality Assurance and Quality Compliance, including significant leadership responsibility for compliance programs and people.
  • Extensive Quality Assurance and Quality Compliance experience within the pharmaceutical, biotechnology, or other highly regulated life sciences industry.
  • Expert knowledge of applicable GxP regulations, regulatory expectations, and industry standards, including relevant FDA regulations and ICH guidelines.
  • Extensive experience developing, leading, and continuously improving risk-based external audit and compliance programs across multiple GxP disciplines.
  • Demonstrated experience with internal audits across multiple regulated areas, which may include Drug Safety/Pharmacovigilance, Clinical Operations, GMP laboratories, and other auditable systems.
  • Demonstrated experience developing, reviewing, and approving audit plans and establishing risk-based approaches to audit planning and execution.
  • Demonstrated experience with regulatory inspection readiness, inspection management, inspection response, and remediation activities.
  • Strong knowledge of Quality Management Systems and governance mechanisms used to evaluate and monitor QMS effectiveness.
  • Demonstrated experience leading or supporting Management Review and presenting quality metrics, trends, risks, compliance issues, and recommendations to senior leadership.
  • Extensive knowledge of quality risk management principles and demonstrated ability to establish risk-based approaches to compliance oversight and decision making.
  • Demonstrated experience developing, conducting, reviewing, and maintaining Quality and compliance risk assessments.
  • Strong understanding of GMP laboratory compliance and applicable regulatory expectations for pharmaceutical laboratory operations.
  • Knowledge of recall management requirements and demonstrated experience supporting or overseeing recall preparedness, governance, coordination, and execution.
  • Demonstrated ability to identify opportunities for SOP improvement and lead development, revision, and implementation of procedures to address regulatory, operational, or compliance needs.
  • Experience developing, reviewing, and updating compliance questionnaires and related assessment tools.
  • Experience with electronic Quality Management Systems and compliance technology platforms.
  • Experience managing or overseeing Quality information within Veeva Organizations, including risk classifications, supplier categories, audit certifications, and related compliance records.
  • Demonstrated ability to identify systemic compliance risks and drive cross-functional corrective, preventive, and continuous improvement initiatives.
  • Experience developing and monitoring compliance metrics, key performance indicators, dashboards, and other mechanisms used to identify trends and support senior management decision making.
  • Demonstrated ability to interpret new and evolving regulatory requirements, assess organizational impact, and develop appropriate compliance strategies.
  • Experience establishing governance frameworks, policies, procedures, and standards that promote sustained inspection readiness and regulatory compliance.
  • Strong knowledge of pharmaceutical development and commercialization environments and the interdependencies among Quality, Clinical Operations, Drug Safety/Pharmacovigilance, Regulatory Affairs, Technical Operations, laboratories, R&D, and other GxP functions.
  • Demonstrated success interacting with senior leadership, regulatory authorities, vendors, and other external stakeholders on significant quality and compliance matters.
  • Proven people leadership experience, including experience leading through other managers, leaders, and/or senior-level professionals.
  • Demonstrated ability to effectively manage resources, priorities, organizational capabilities, and functional operating plans within a complex Quality organization.
  • Consistently acts as a trusted advisor across the organization and provides strategy, vision, and direction on matters that may have company-wide impact.
  • Deep expertise within Quality Assurance and Quality Compliance, combined with broad understanding of pharmaceutical development, manufacturing, regulatory requirements, and related GxP functions.
  • Demonstrated ability to develop and execute long-term functional strategies and translate complex organizational objectives into actionable operating plans.
  • Demonstrated ability to anticipate factors that could impact company strategy, regulatory compliance, operational effectiveness, or the company's position within the industry.
  • Proven ability to evaluate complex and ambiguous issues, assess multiple variables and risks, and develop innovative, practical, and sustainable solutions.
  • Strong business acumen and ability to balance regulatory requirements, patient protection, quality risk, operational priorities, and business objectives in complex decision making.
  • Demonstrated ability to influence senior management and executive leadership and align stakeholders across organizational and functional boundaries.
  • Exceptional written and verbal communication skills, including the ability to communicate complex compliance matters clearly and effectively to executive leadership, regulatory authorities, and diverse internal and external audiences.
  • Proven leadership skills with demonstrated ability to build, develop, mentor, motivate, and retain high-performing teams and leaders.
  • Demonstrated ability to lead through organizational change and establish accountability for execution, ethical standards, compliance, and results.
  • Strong strategic thinking, decision quality, problem-solving, analytical, and risk-management capabilities.
  • Demonstrated ability to establish organizational priorities, frameworks, policies, and processes that support long-term functional success.
  • Demonstrated ability to build impactful cross-functional teams and foster collaboration, engagement, accountability, continuous learning, and high performance.
  • Ability to operate effectively in a complex, evolving, and highly regulated environment while maintaining a long-term strategic and enterprise perspective.
  • Demonstrated ability to develop organizational capability and talent, including mentoring leaders, succession planning, and building a strong leadership bench.
  • Ability to assess functional performance, establish meaningful success measures, and drive results through managers, senior professionals, and cross-functional partners.
Responsibilities
  • Provide strategic leadership and direction for the Quality Compliance function, establishing multi-year strategies, priorities, operating plans, and objectives aligned with broader Quality and company goals.
  • Lead the external audit program and establish a risk-based audit strategy encompassing GxP vendors and service providers.
  • Own the supplier/vendor quality management system and associated policies aligned with applicable standards, including ISO 9001, ISO 13485, GxP, or industry-specific standards.
  • Define quality requirements, acceptance criteria, and key performance indicators for vendor onboarding and ongoing performance.
  • Establish and maintain vendor quality agreements and quality technical agreements.
  • Lead supplier qualification, requalification, and risk-based audit programs.
  • Segment and score vendors by quality/compliance risk criticality.
  • Maintain business continuity and contingency plans for high-risk or critical suppliers.
  • Partner with Procurement on risk-informed vendor selection and contract terms.
  • Conduct or oversee on-site and remote audits of quality systems, manufacturing processes, and documentation practices.
  • Approve, conditionally approve, or disqualify vendors based on audit findings and risk assessments.
  • Lead the internal audit program and establish a risk-based audit strategy encompassing applicable GxP systems and functions, including Drug Safety/Pharmacovigilance, Clinical Operations, GMP laboratories, and other auditable systems.
  • Provide strategic oversight of the annual internal audit plan, including risk-based prioritization, governance, execution, escalation of significant findings, and monitoring of corrective and preventive actions.
  • Establish and maintain an organizational inspection readiness program to ensure ongoing preparedness for regulatory inspections and other external assessments.
  • Maintain audit-ready documentation and evidence for internal and external inspections.
  • Monitor regulatory changes and update vendor compliance requirements accordingly.
  • Manage vendor-related regulatory findings, warning letters, or non-conformance.
  • Provide leadership and strategic direction during regulatory inspections, including inspection preparation, coordination, response strategy, remediation, and management of inspection commitments, as applicable.
  • Lead Quality Management Review activities, ensuring senior leadership has appropriate visibility to quality performance, compliance trends, emerging risks, significant quality issues, and effectiveness of compliance programs.
  • Provide strategic oversight for GMP laboratory compliance and partner with applicable Quality, Technical Operations, and laboratory stakeholders to identify, assess, and mitigate compliance risks.
  • Lead and continuously improve the Quality risk management framework, including development and oversight of risk assessments and processes for identifying, evaluating, escalating, mitigating, and monitoring significant quality and compliance risks.
  • Provide strategic oversight of recall management processes and ensure appropriate governance, cross-functional coordination, escalation, and execution of product recall activities, as applicable.
  • Drive continuous improvement of SOPs, compliance processes, tools, and governance mechanisms based on regulatory expectations, inspection and audit trends, business needs, and identified risks.
  • Establish meaningful compliance metrics, dashboards, and key performance indicators to monitor organizational compliance, identify trends, and inform risk-based decision making and management review.
  • Provide governance and strategic oversight for Quality Compliance data and systems, including applicable Veeva organizations, risk classifications, supplier categories, audit certifications, questionnaires, and related compliance information.
  • Ensure risk classifications, compliance questionnaires, and other compliance assessment tools are periodically reviewed and updated to reflect evolving regulatory requirements and business needs.
  • Serve as a senior Quality Compliance advisor to Quality leadership and cross-functional stakeholders on complex or high-risk compliance matters.
  • Interpret emerging regulatory requirements and industry trends and assess their potential impact to Quality operations and compliance strategy.
  • Partner across Quality and with Clinical Operations, Drug Safety/Pharmacovigilance, Technical Operations, Regulatory Affairs, R&D, and other functions to drive integrated and sustainable compliance solutions.
  • Promote organizational awareness of quality and compliance expectations through effective communication, education, and compliance-related communications and initiatives.
  • Develop, lead, mentor, and retain a high-performing Quality Compliance organization; establish clear expectations and accountability while building organizational capability and succession readiness.
  • Provide leadership through subordinate leaders and/or high-level professionals and effectively manage resources, priorities, and organizational capabilities required to achieve Quality Compliance objectives.
  • Champion a culture of quality, integrity, accountability, risk-based decision making, continuous improvement, and proactive compliance throughout the organization.
  • Perform other duties as assigned.
Desired Qualifications
  • Prior experience leading a Quality Compliance function or major compliance organization, including responsibility for external and internal audits, regulatory inspection readiness, Management Review, quality risk management, GMP compliance, and senior-level compliance governance.
  • Experience with Veeva Quality applications.

About the company

N

Neurocrine Biosciences

View

Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Get referred to Neurocrine Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue jumped 39.5% to $959 million, beating estimates.
  • Neurocrine raised 2026 INGREZZA guidance to $2.825 billion-$2.875 billion after strong prescriptions.
  • NBIP-1968 entered Phase 1 in August 2026, giving Neurocrine obesity upside.

What critics are saying

  • INGREZZA faces Zydus generic litigation after the March 2025 ANDA challenge.
  • DOJ requested INGREZZA sales documents in August 2025, threatening fines or restrictions.
  • VYKAT XR drew safety alarms in August 2026 after reported deaths and hospitalizations.

What makes Neurocrine Biosciences unique

  • INGREZZA led Neurocrine's CNS franchise, with Q2 2026 sales of $716 million.
  • CRENESSITY delivered $184 million in Q2 2026, validating Neurocrine's endocrinology expansion.
  • Soleno acquisition added VYKAT XR, the only approved PWS hyperphagia therapy, in May 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Parental Leave
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Holidays

Company News

Yahoo Finance
Oct 24th, 2026
Neurocrine's VYKAT XR gets expert backing in PWS as analysts eye $1.3B earnings by 2029

Neurocrine Biosciences has reported an expert publication on hyperphagia in Prader-Willi syndrome (PWS). The paper describes the condition as a complex neurobiological disorder and names VYKAT XR as the first US Food and Drug Administration-approved therapy for this symptom. The publication backs VYKAT XR as part of multidisciplinary PWS care. Investor focus still likely rests on pricing pressure for INGREZZA, the company's main product, as Medicare-related headwinds build into 2027. CRENESSITY, another rare disease drug, brought in about $184 million in quarterly net sales. An estimated 15% of diagnosed patients with congenital adrenal hyperplasia are already treated. Analysts expect revenue to grow 14.6% a year. They project earnings to rise from $705.5 million to $1.3 billion by 2029.

Biotech Insider
Oct 18th, 2026
OMass secures $310M to challenge rare-disease incumbent.

OMass secures $310M to challenge rare-disease incumbent. OMass has secured $310 million for a rare endocrine disease drug, setting up a development contest with Neurocrine and a potential Vertex rival. OMass secured $310 million to advance a drug candidate for congenital adrenal hyperplasia, seeking to compete with Neurocrine Biosciences' FDA-approved therapy. OMass has secured $310 million to advance a drug for congenital adrenal hyperplasia, giving the startup funding to pursue a market where an approved treatment already exists and another potential competitor is emerging. The financing puts the business challenge alongside the scientific one. OMass must develop a medicine that can satisfy regulators while establishing why patients and physicians would choose it over an existing option. Funding can support that effort, but it does not establish that the molecule works or that it will become commercially competitive. Neurocrine Biosciences has the drug described as the only FDA-approved therapy for congenital adrenal hyperplasia. Vertex Pharmaceuticals could also enter the competitive picture through a candidate obtained in a recent acquisition. OMass's financing and the potential rivalry were reported by MedCity News. Funding buys development capacity, not an approval. The central fact is the $310 million secured to advance OMass's drug. That gives the company a financing base for development, an important distinction from having demonstrated clinical success. The value of the funding will ultimately depend on the evidence it helps the company produce. Drug development requires choices about which studies to conduct, what questions to answer and how to prepare for regulatory review. Financing can make those choices less dependent on an immediate search for additional capital. It cannot eliminate the possibility of disappointing results, unexpected safety findings or requests for more evidence. The available information does not specify OMass's clinical development stage, the financing structure, how the money will be allocated or how long it is expected to last. It therefore does not support describing the candidate as late-stage, assigning a launch timetable or estimating the company's cash runway - the period it can operate before needing more funding. Those omissions matter to an assessment of the deal. The same funding amount can have different implications depending on the studies ahead and the resources they require. The next useful development disclosure would connect the financing to a defined program and explain which milestone the company expects it to support. An approved rival sets the competitive baseline. Neurocrine's position changes the question facing OMass. The startup is not simply pursuing a treatment in a market without an approved competitor. It is seeking to offer an alternative to a drug that has already cleared the regulatory threshold described in the report. That makes differentiation - the evidence that a product offers a meaningful distinction - central to the commercial case. A future alternative might compete on treatment effect, safety, tolerability or practical use. None of those advantages has been established for OMass's molecule by the information available here. Investors should distinguish between the ambition to become an alternative and evidence of superiority. Approval of another drug does not prove OMass's approach will succeed. Nor does OMass need to be described as superior for its development to matter: an additional approved option could expand treatment choice, depending on its eventual evidence and label. For patients and clinicians, the relevant question is whether a new medicine would provide a useful choice in actual care. For the company, that question also shapes the evidence it may need to persuade prescribers and payers. Regulatory clearance and commercial adoption are related goals, but they are not interchangeable. Vertex adds uncertainty to the future market. For patients and clinicians, the relevant question is whether a new medicine would provide a useful choice in actual care. Vertex's potential participation makes the competitive landscape less settled than a simple contest between a startup and an incumbent. Its candidate came through a recent acquisition, giving the financing story a parallel business-development dimension: a company can build a position by funding internal work or acquiring an external program. The supplied facts do not identify the acquired company, the transaction value, the candidate's stage or its development schedule. They also do not establish that Vertex's drug will reach the market. Its role should therefore be treated as potential competition, not as an approved rival or a guaranteed entrant. Even so, the possibility is relevant to OMass's planning. A development strategy must account for the treatment landscape that could exist when a candidate becomes available, rather than assuming today's landscape will remain unchanged. Clinical progress elsewhere could affect how a new entrant needs to distinguish itself. For now, there is no basis to rank OMass's candidate against Vertex's or to predict which could arrive first. The useful comparison will come from disclosed study designs, results and regulatory progress, not from the financing amount or the fact of an acquisition alone. The latest stock closes are not a reaction to the funding. The supplied market snapshot offers context for the listed competitors, but its timing limits what it can say about this news. Neurocrine's NBIX shares closed down 0.91%, while Vertex's VRTX shares closed down 1.77% in the most recent session, with last trades recorded on October 16, 2026, at 20:00 GMT. Those closes preceded the October 18 report of OMass's financing. They should not be read as a market response to the funding or as an investor verdict on the startup's competitive prospects. Establishing such a response would require subsequent market data and consideration of other company and market developments. The next test is a clearer development plan. The financing gives OMass resources to pursue its objective, but the next assessment should turn on development specifics. A confirmed clinical stage, a description of the studies being funded and a clear account of the next evidence milestone would make the program easier to evaluate. Results would then need to be judged on what they demonstrate, including the patients studied, the outcomes measured and the safety findings. Comparisons across separate trials require care because different study designs can make apparent differences misleading. The business significance is clear without assuming a successful outcome: OMass has secured substantial funding to pursue an alternative in a rare endocrine disorder with an established approved competitor and a possible additional entrant. Converting that capital into a credible treatment choice remains the task ahead. Key facts. * Funding secured: OMass secured $310 million to advance its rare endocrine disorder drug. * Target condition: Congenital adrenal hyperplasia; the candidate's clinical development stage was not specified. * Approved competitor: Neurocrine Biosciences (NBIX): shares closed down 0.91%; last trade October 16, 2026, at 20:00 GMT. * Potential competitor: Vertex Pharmaceuticals (VRTX): shares closed down 1.77%; last trade October 16, 2026, at 20:00 GMT. Frequently asked questions. What did OMass secure the $310 million for? OMass secured $310 million to advance a drug candidate for congenital adrenal hyperplasia, a rare endocrine disorder. The funding supports its effort to develop an alternative to Neurocrine Biosciences' approved therapy. The available information does not specify the financing structure, spending allocation or expected cash runway. What stage is OMass's drug candidate in? The supplied information does not identify the clinical development stage of OMass's candidate. It would therefore be premature to call the drug late-stage or estimate when it might reach patients. A disclosed development plan and study milestones would help establish what the financing is intended to accomplish. How does Neurocrine Biosciences compete with OMass? Neurocrine Biosciences has the drug described as the only FDA-approved therapy for congenital adrenal hyperplasia. OMass is developing a potential alternative. That creates a need for OMass to establish its candidate's clinical value, but the available facts do not show that its molecule is safer, more effective or more convenient. Why is Vertex Pharmaceuticals relevant to the financing? Vertex Pharmaceuticals could compete through a drug candidate obtained in a recent acquisition. That makes it a potential additional rival as OMass advances its program. The supplied facts do not identify the acquisition target, transaction value, candidate stage or timeline, so Vertex's eventual market entry remains uncertain. Did Neurocrine and Vertex shares react to OMass's funding? The supplied stock data cannot establish a reaction. Neurocrine shares closed down 0.91% and Vertex shares closed down 1.77% on October 16, 2026, before the October 18 financing report. Those moves should not be attributed to OMass's funding without later market data and evidence connecting the news to trading. What should investors watch next from OMass? Investors should watch for a confirmed development stage, the studies the funding will support and the next evidence milestone. Clinical results and regulatory progress will be more informative than the financing amount alone. Any comparison with competing drugs should account for differences in study populations, design and measured outcomes.

Contract Pharma
Sep 29th, 2026
Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer.

Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer. September 29, 2026 Content Marketing Editor Why This Matters: See our coverage of other industry executive team appointments and promotions here. Neurocrine Biosciences named Eiry Roberts, MD, Chief Medical Officer, returning Roberts to a post she held from 2018 to 2025. Roberts had remained linked with Neurocrine in the intervening time as a Strategic Advisor. Resulting from this appointment, Sanjay Keswani, MD, is departing Neurocrine by mutual agreement. Chief Medical Officer's resume. During her previous tenure, Roberts led indication expansion efforts for Ingrezza (valbenazine). She also spearheaded the development program that led to U.S. FDA approval of Crenessity (crinecerfont). Before joining Neurocrine, Roberts spent 26 years at Eli Lilly and Company, most notably as Vice President, Research and Development. Roberts served on the Board of Directors of Amicus Therapeutics prior to its April 2026 acquisition by BioMarin Pharmaceutical. Currently, she serves on the Board of Directors of Bausch Health Companies. Her new appointment as CMO at Neurocrine takes effect immediately. New meets familiar at Neurocrine. "I'm honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering," Roberts said. "Having remained closely connected to the company as a Strategic Advisor, I am excited about the opportunities ahead. I look forward to building on the teams' progress, advancing the portfolio, and ultimately delivering meaningful benefits for patients." "We're pleased to welcome Eiry back to the Chief Medical Officer role," Neurocrine President and CEO Kyle Gano, PhD, said. "Her deep knowledge of Neurocrine, our pipeline, and our clinical development programs provides strong continuity... Eiry's experience with our portfolio positions her well to lead our clinical development efforts. I look forward to working closely with her once again." Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

PR Newswire
Sep 28th, 2026
Neurocrine Biosciences reappoints Eiry Roberts as chief medical officer

Neurocrine Biosciences has reappointed Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr Roberts previously held the CMO position from 2018 to 2025 and has since served as a strategic adviser to the company. During her earlier tenure, Dr Roberts led indication-expansion efforts for INGREZZA and the crinecerfont development programme that resulted in FDA approval of CRENESSITY. Before joining Neurocrine in 2018, she spent 26 years at Eli Lilly and Company in senior research and development roles. By mutual agreement, Sanjay Keswani, M.D., will depart the company. CEO Kyle W. Gano noted that Dr Roberts' knowledge of Neurocrine's pipeline positions her well to lead clinical development efforts as the company advances multiple late-stage programmes.

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)